Skip to content

    Melanoma/Skin Cancer Health Center

    Medical Reference Related to Melanoma Skin Cancer

    1. Melanoma Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Option Overview

      There are different types of treatments for patients with intraocular melanoma. Different types of treatments are available for patients with intraocular melanoma. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.Five types of standard treatment are used:SurgerySurgery is the most common treatment for intraocular melanoma. The following types of surgery may be used:Resection: Surgery to remove the tumor and a small amount of healthy tissue around it.Enucleation: Surgery to remove the eye and part of

    2. Melanoma Treatment (PDQ®): Treatment - Patient Information [NCI] - About This PDQ Summary

      About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current

    3. Melanoma Treatment (PDQ®): Treatment - Patient Information [NCI] - To Learn More About Skin Cancer

      For more information from the National Cancer Institute about skin cancer, see the following:Skin Cancer Home PageWhat You Need to Know About™ Melanoma and Other Skin CancersSkin Cancer PreventionSkin Cancer ScreeningUnusual Cancers of ChildhoodCryosurgery in Cancer Treatment: Questions and AnswersLasers in Cancer TreatmentDrugs Approved for Basal Cell CarcinomaPhotodynamic Therapy for CancerFor general cancer information and other resources from the National Cancer Institute, see the following:What You Need to Know About™ CancerUnderstanding Cancer Series: CancerCancer StagingChemotherapy and You: Support for People With CancerRadiation Therapy and You: Support for People With CancerCoping with Cancer: Supportive and Palliative CareQuestions to Ask Your Doctor About CancerCancer LibraryInformation For Survivors/Caregivers/Advocates

    4. Melanoma Treatment (PDQ®): Treatment - Patient Information [NCI] - nci_ncicdr0000258035-nci-header

      This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at or call 1-800-4-CANCER.Skin Cancer Treatment

    5. Melanoma Treatment (PDQ®): Treatment - Patient Information [NCI] - Psychosocial Issues in Familial Melanoma

      This section reviews the literature examining risk reduction and early-detection behaviors in individuals with heightened risk of melanoma resulting from their family history of the disease and in individuals from hereditary families who have been tested for melanoma high-risk mutation status. The review also addresses risk perception and communication in individuals at heightened risk of melanoma.Motivation and Interest in Genetic Testing for Risk of MelanomaFew studies have examined motivation and interest in genetic testing for melanoma risk. In general, the findings include the following: High, but not universal interest in genetic testing.Articulated benefits of testing among those at heightened risk.A relative lack of examination of potential limitations of testing or reasons to forgo testing.In Australia, a qualitative study (N = 40) found that almost all participants with a strong family history of melanoma were interested in genetic testing.[1,2] Genetic testing was favored

    6. Metastatic Squamous Neck Cancer with Occult Primary Treatment (PDQ®): Treatment - Patient Information [NCI] - Changes to This Summary (03 / 05 / 2014)

      The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above. Editorial changes were made to this summary.

    7. Melanoma Treatment (PDQ®): Treatment - Patient Information [NCI] - Recurrent Intraocular Melanoma

      The prognosis for any patient with recurring or relapsing disease is poor, regardless of cell type or stage. The question and selection of further treatment depends on many factors, including the extent of the lesion, age and health of the patient, prior treatment, and site of recurrence, as well as individual patient considerations. Surgical resection of metastases diagnosed subsequent to initial management of ocular melanoma in single-center, case series of highly selected patients has been reported. The extent to which the occasional favorable outcomes are the result of strong selection factors is not clear, so this approach cannot be considered standard.[1]Clinical trials are appropriate, and eligible patients should be advised to consider participation in them whenever possible. Current Clinical TrialsCheck for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with recurrent intraocular melanoma. The list of clinical trials can be

    8. Melanoma Treatment (PDQ®): Treatment - Patient Information [NCI] - Stage I Melanoma Treatment

      Stage I melanoma is defined by the American Joint Committee on Cancer's TNM classification system:[1]T1a, N0, M0T1b, N0, M0T2a, N0, M0Standard Treatment Options for Patients With Stage I MelanomaCurrent evidence suggests that lesions 2 mm or less in thickness may be treated conservatively with radial excision margins of 1 cm. A randomized trial compared narrow margins (1 cm) with wide margins (at least 3 cm) in patients with melanomas no thicker than 2 mm.[2,3] No difference was observed between the two groups in respect to the development of metastatic disease, disease-free survival (DFS), or overall survival (OS). Two other randomized trials compared 2 cm margins with wider margins (i.e., 4 cm or 5 cm) and found no statistically significant difference in local recurrence, distant metastasis, or OS with a median follow-up of 10 years or more for both trials.[4,5,6][Level of evidence:1iiA] In the Intergroup Melanoma Surgical Trial, the reduction in margins from 4 cm to 2 cm was

    9. Melanoma Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options for Actinic Keratosis

      Actinic keratosis is not cancer but is treated because it may develop into cancer. Treatment of actinic keratosis may include the following:Topical chemotherapy.Topical biologic therapy with imiquimod.Cryosurgery.Electrodesiccation and curettage.Dermabrasion.Shave excision.Photodynamic therapy.Laser surgery.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with actinic keratosis. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.

    10. Melanoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Cellular and Molecular Classification of Melanoma

      Following is a list of clinicopathologic cellular subtypes of malignant melanoma. These should be considered descriptive terms of historic interest only as they do not have independent prognostic or therapeutic significance. Superficial spreading.Nodular.Lentigo maligna.Acral lentiginous (palmar/plantar and subungual).Miscellaneous unusual types: Mucosal lentiginous (oral and genital).Desmoplastic.Verrucous. Identification of activating mutations in the mitogen-activated protein kinase pathway has led to the definition of molecular subtypes of melanoma and provided potential drug targets.BRAF (V-raf murine sarcoma viral oncogene homolog B1) gene, first reported in 2002, are the most frequent mutation in cutaneous melanoma. Approximately 40% to 60% of malignant melanomas harbor a single nucleotide transversion. The majority have a mutation that results in a substitution from valine to glutamic acid at position 600 BRAF (V600E); less frequent mutations include valine 600 to lysine or

    Displaying 101 - 110 of 168 Articles << Prev Page 7 8 9 10 11 12 13 14 15 16 Next >>

    Today on WebMD

    Malignant melanoma
    How to spot it early.
    Woman checking out tan lines
    There’s a dark side to that strive for beauty.
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Lung cancer xray
    See it in pictures, plus read the facts.
    12 Ways to Protect Your Skin from Melanoma
    precancerous lesions slideshow
    Do You Know Your Melanoma ABCs
    15 Cancer Symptoms Men Ignore
    screening tests for men
    Vitamin D
    Is That Mole Skin Cancer
    Brilliant sun rays